Phase 2 Haemophilia Trial, Recruiting NCT06120582 Sponsor: Biocad Condition: Haemophilia
Back to Haemophilia

Phase 2 Haemophilia Trial, Recruiting

NCT06120582
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male and have been diagnosed with hemophilia B
  • You are 18 years of age or older
  • Your Factor IX (the clotting protein affected in hemophilia B) level is 2% or less, and you do not have inhibitors (antibodies that block the treatment) (confirm with trial site)
  • You have received Factor IX treatment products on at least 150 separate days in the past

Who may not be able to join:

  • You have previously received any type of gene therapy
  • You have another blood or bone marrow disorder in addition to hemophilia B
  • You have certain antibodies in your blood that could interfere with the trial treatment (confirm with trial site)
  • You have HIV that is not being successfully controlled with antiviral medication
  • You have hepatitis B or active/chronic hepatitis C infection (confirm with trial site for which parts of the trial this applies to)
  • You currently have an active infection throughout your body, or you frequently get infections that need systemic (whole-body) treatment
  • You have any other condition that seriously weakens your immune system
  • You have significant liver disease, such as liver cirrhosis or liver scarring (fibrosis)
  • You have had a cancer diagnosis and have been in remission for less than 5 years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Arina V Zinkina-Orikhan, MD, Director of Clinical Development Department, BIOCAD

Phone: +7 (812) 380 49 34

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Biocad
Registry
ClinicalTrials.gov
Start date
2 May 2023
Est. completion
1 November 2025

Where this trial is recruiting

Belarus 🇷🇺 Russia

Primary endpoints

Change in FIX activity from baseline; Proportion of subjects with adverse reactions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov